Clinical trials were made with glycodiazine, N.(5(2-Methoxyethoxy)-2-Pyrimidinyl) benzenesulfonamide by a technic in which the effects of the drug were compared statistically to those of a placebo in a group of patients with the adult onset type of diabetes mellitus. Glycodiazine was active orally at two dosage levels 0.5 gm. b.i.d. and 0.5 grn. once a day although onset of antihyperglycemic response was slower with the smaller dose. No untoward side effects were noticed. The findings indicate that glycodiazine may be an effective oral antihyperglycemic agent.

This content is only available via PDF.